Abstract:Background: Cancer stem cells (CSCs) play a crucial role in tumor recurrence and metastasis, which are the primary causes of death in patients with hepatocellular carcinoma (HCC). Currently, no drug effectively blocks the recurrence and metastasis of liver cancer, leading to a poor prognosis for patients. To enhance treatment outcomes, there is an urgent need to investigate the molecular mechanisms behind the recurrence and progression of liver cancer, with the aim of identifying effective therapeutic targets. Targeting HCC stemness can improve the prognosis of patients with HCC. Abnormal spindle-like microcephaly-associated protein (ASPM) plays a pivotal role in regulating neurogenesis and brain size, which is a centrosome protein. ASPM has been implicated in tumorigenesis and tumor progression, but its regulatory role in HCC stemness is not well understood. This study aims to investigate the role of ASPM in liver cancer stemness and elucidate its potential molecular mechanisms. Methods: Bioinformatics analysis was used to study the expression of ASPM and its clinical significance in HCC. In vitro and in vivo assays were conducted to clarify the impact of ASPM knockdown on HCC cell stemness. The correlation between ASPM and the Wnt/β-catenin pathway was examined through analysis of online databases and in vitro experiments. Results: The bioinformatics analysis revealed significant upregulation of ASPM was significantly upregulated in HCC samples, with expression correlating with poor prognosis. In vitro experimental data confirmed elevated ASPM expression in HCC cells compared to normal hepatocytes. Knockdown of ASPM suppressed HCC cell growth, clone formation, spheroid formation, migration, invasion, and the expression of CSC markers CD133 and CD44. This also inhibited the activation of the Wnt/β-catenin pathway. Reactivation of this pathway partially reversed the biological changes induced by ASPM knockdown in HCC cells. Additionally, in vivo data demonstrated that ASPM downregulation reduced the size and weight of xenografts in BALB/c mice, along with decreased expression of CSC markers. Conclusions: These findings suggest that ASPM promotes HCC stemness and progression through the Wnt/β-catenin pathway. Targeting ASPM or the Wnt/β-catenin pathway may be a promising strategy to prevent HCC chemoresistance and recurrence, ultimately improving patient prognosis.

ASPP2 Suppresses Stem Cell-Like Characteristics and Chemoresistance by Inhibiting the Src/FAK/Snail Axis in Hepatocellular Carcinoma

ASPP2 Suppresses Tumour Growth and Stemness Characteristics in HCC by Inhibiting Warburg Effect Via WNT/β‐catenin/HK2 Axis

Downregulation of ASPP2 improves hepatocellular carcinoma cells survival via promoting BECN1-dependent autophagy initiation

SRSF10 Facilitates HCC Growth and Metastasis by Suppressing CD8+T Cell Infiltration and Targeting SRSF10 Enhances Anti-Pd-l1 Therapy

Epigenetic Silence of Ankyrin-Repeat-Containing, Sh3-Domain-Containing, and Proline-Rich-Region-Containing Protein 1 (aspp1) and Aspp2 Genes Promotes Tumor Growth in Hepatitis B Virus-Positive Hepatocellular Carcinoma

mRNA sequencing and CyTOF analysis revealed ASPP2 altered the response patterns of hepatocellular carcinoma HepG2 cells to usnic acid

Aberrantly regulated dysadherin and B-cell lymphoma 2/B-cell lymphoma 2-associated X enhances tumorigenesis and DNA targeting drug resistance of liver cancer stem cells.

Promotion of hepatocellular carcinoma stemness and progression by abnormal spindle-like microcephaly-associated protein via the Wnt/β-catenin pathway

HDAC1-induced Epigenetic Silencing of ASPP2 Promotes Cell Motility, Tumour Growth and Drug Resistance in Renal Cell Carcinoma.

YY1-regulated lncRNA SOCS2-AS1 suppresses HCC cell stemness and progression via miR-454-3p/CPEB1

ASPP2 Controls Epithelial Plasticity and Inhibits Metastasis Through Β-Catenin-dependent Regulation of ZEB1.

Shp2 Promotes Liver Cancer Stem Cell Expansion by Augmenting Β‐catenin Signaling and Predicts Chemotherapeutic Response of Patients

Asperulosidic Acid Restrains Hepatocellular Carcinoma Development and Enhances Chemosensitivity Through Inactivating the MEKK1/NF-κB Pathway

Downregulation of SSR2 Enhances Hepatocellular Carcinoma Cisplatin Sensitivity via the Hippo Pathway

Silencing of ASPP 2 Promotes the Proliferation , Migration and Invasion of Triple-Negative Breast Cancer Cells Via the PI 3 K / AKT Pathway

Epigenetic Silencing Of Aspp1 Confers 5-Fu Resistance In Clear Cell Renal Cell Carcinoma By Preventing P53 Activation

ASPM Promotes Hepatocellular Carcinoma Progression by Activating Wnt/β‐catenin Signaling Through Antagonizing Autophagy‐mediated Dvl2 Degradation

Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation

Increased Expression of Iaspp, Regulated by Hepatitis B Virus X Protein-Mediated NF-κB Activation, in Hepatocellular Carcinoma

Inhibition of SPATS2 Suppresses Proliferation and Invasion of Hepatocellular Carcinoma Cells Through TRIM44-STAT3 Signaling Pathway

ASPP2 attenuates triglycerides to protect against hepatocyte injury by reducing autophagy in a cell and mouse model of non-alcoholic fatty liver disease